Skip to main content
Citius Pharmaceuticals, Inc. logo

Citius Pharmaceuticals, Inc. — Investor Relations & Filings

Ticker · CTXR ISIN · US17322U2078 LEI · 5493005C10W36P4KQP40 US Manufacturing
Open in API
Filings indexed 623 across all filing types
Latest filing 2016-01-19 Regulatory Filings
Country US United States of America
Listing US CTXR

About Citius Pharmaceuticals, Inc.

https://www.citiuspharma.com/

Citius Pharmaceuticals, Inc. is a late-stage biopharmaceutical company that develops and commercializes critical care products. The company's diversified pipeline focuses on anti-infectives in adjunct cancer care, stem cell therapies, and prescription products. Its portfolio includes LYMPHIR™, an FDA-approved therapy for adult patients with relapsed or refractory cutaneous T-cell lymphoma (CTCL). Key product candidates in development include Mino-Lok®, an antibiotic lock solution intended to treat patients with catheter-related bloodstream infections, and Halo-Lido, a topical formulation for the treatment of hemorrhoids. Additionally, the company is advancing a stem cell therapy platform for conditions such as acute respiratory distress syndrome (ARDS).

Recent filings

Filing Released Lang Actions
Regulatory Filings 2016
Regulatory Filings Classification · 95% confidence The document is a letter from Citius Pharmaceuticals, Inc. to the SEC requesting acceleration of the effective date of a Registration Statement on Form S-1. It references Rule 461 under the Securities Act of 1933 and discusses the effectiveness of the filing. The document is short (1653 characters) and is a correspondence related to a regulatory filing, not the filing itself. It does not contain financial data or detailed report content but is an official communication about the registration statement's effective date. Therefore, it fits best under Regulatory Filings (RNS), which covers general regulatory announcements and correspondence with the SEC that do not fit other categories.
2016-01-19 English
Regulatory Filings 2016
Regulatory Filings Classification · 95% confidence The document is a letter from Citius Pharmaceuticals, Inc. to the SEC requesting acceleration of the effective date for a Registration Statement on Form S-1. It references Rule 461 under the Securities Act of 1933 and discusses the effectiveness of the registration statement. The document is short (1634 characters) and is a correspondence related to a regulatory filing, not a financial report or detailed filing itself. It does not contain financial data or detailed report content but is an official regulatory communication. Therefore, it fits best under Regulatory Filings (RNS).
2016-01-19 English
FORM S-1/A
Capital/Financing Update Classification · 100% confidence The document is a Form S-1/A, which is an amendment to a registration statement filed with the SEC under the Securities Act of 1933. It is used for registering securities for public offering, including details about the offering, selling shareholders, use of proceeds, risk factors, and other disclosures relevant to investors. The text includes references to registration fees, securities to be registered, selling shareholders, plan of distribution, and other typical content of a registration statement prospectus. This is not an annual report, earnings release, or any other financial report but a capital markets filing related to securities registration and offering. Therefore, the appropriate classification is Capital/Financing Update (CAP). The document length and detail confirm it is the actual registration statement amendment, not just an announcement or notice, so it is not RPA or RNS. Confidence is high given the clear identification of the form and content.
2016-01-12 English
Regulatory Filings 2016
Regulatory Filings
2016-01-08 English
FORM S-1/A
Capital/Financing Update Classification · 100% confidence The document is a Form S-1/A, which is an amendment to a registration statement filed with the SEC under the Securities Act of 1933. It is used for registering securities for public offering, including details about the offering, selling shareholders, and related information. The text includes details about the securities being registered, the offering price, and the business overview, typical of a registration statement prospectus. This is not an annual report, earnings release, or other financial report but a capital markets filing related to securities registration and offering. Therefore, the appropriate classification is Capital/Financing Update (CAP). The document length and content confirm it is a full registration statement amendment, not a brief announcement or certification, so it is not RNS or RPA.
2015-12-29 English
FORM 10-K
Annual Report FY 2015
2015-12-14 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.